T. Rowe Price Investment Management, Inc. Syndax Pharmaceuticals Inc Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,459,235 shares of SNDX stock, worth $47.4 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,459,235
Previous 2,711,253
9.3%
Holding current value
$47.4 Million
Previous $58.6 Million
0.1%
% of portfolio
0.04%
Previous 0.04%
Shares
6 transactions
Others Institutions Holding SNDX
# of Institutions
195Shares Held
90MCall Options Held
353KPut Options Held
207K-
Black Rock Inc. New York, NY7.55MShares$146 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA7.44MShares$143 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.66MShares$109 Million14.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.93MShares$94.9 Million0.0% of portfolio
-
State Street Corp Boston, MA4.82MShares$92.9 Million0.01% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $1.09B
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...